deltatrials
Completed PHASE4 NCT00379028

Airway Clearance Study

A Randomized, Double-blind, Two-way Cross-over Study Evaluating Systemic Bioavailability and Airway Clearance of SymbicortTurbuhaler 320/9mcg vs SeretideDiskus 50/500mcg After Single Inhalations in Patients With COPD and Healthy Volunteers

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease
Interventions Budesonide/Formoterol Turbuhaler Salmeterol/Fluticasone Diskus
Updated 5 times since 2017 Last updated: Jan 21, 2011 Started: Sep 30, 2006 Completion: Jul 31, 2007

Listed as NCT00379028, this PHASE4 trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Lund, Sweden
  • • Nottingham, United Kingdom